A neutralising activity was observed in 15 of 21 positive sera; in other words, 15 of 84 (18%) critically ill COVID‐19 patients had neutralising anti‐IFN‐α auto‐Abs (Figure 1a). This evidence concerns the gene DDX41 and COVID-19.